Verona Pharma (VRNA)
(Delayed Data from NSDQ)
$16.10 USD
-0.30 (-1.83%)
Updated Apr 18, 2024 04:00 PM ET
After-Market: $16.43 +0.33 (2.05%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth F Momentum F VGM
Balance Sheet
Fiscal Year End for Verona Pharma PLC American Depositary Share falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 272 | 228 | 148 | 188 | 39 |
Receivables | 11 | 9 | 16 | 8 | 9 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 7 | 6 | 6 | 6 | 4 |
Total Current Assets | 290 | 243 | 170 | 203 | 52 |
Net Property & Equipment | 0 | 0 | 0 | 0 | 0 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 1 | 1 | 1 | 1 | 4 |
Deposits & Other Assets | 15 | 15 | 15 | 0 | 0 |
Total Assets | 308 | 259 | 187 | 204 | 58 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 3 | 3 | 10 | 0 | 11 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 1 | 1 | 1 | 1 | 1 |
Accrued Expenses | 4 | 14 | 22 | 11 | 0 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 1 | 0 | 2 | 1 |
Total Current Liabilities | 9 | 19 | 33 | 14 | 12 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 48 | 10 | 5 | 5 | 0 |
Non-Current Capital Leases | 2 | 0 | 0 | 1 | 1 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 1 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 59 | 29 | 39 | 19 | 14 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 43 | 41 | 32 | 32 | 7 |
Capital Surplus | 601 | 529 | 385 | 366 | 152 |
Retained Earnings | -388 | -333 | -264 | -207 | -128 |
Other Equity | -5 | -5 | -5 | -5 | 13 |
Treasury Stock | 2 | 2 | 1 | 2 | 0 |
Total Shareholder's Equity | 249 | 230 | 148 | 185 | 43 |
Total Liabilities & Shareholder's Equity | 308 | 259 | 187 | 204 | 58 |
Total Common Equity | 249 | 230 | 148 | 185 | 43 |
Shares Outstanding | 80.40 | 75.60 | 60.00 | 57.90 | 13.10 |
Book Value Per Share | 3.10 | 3.05 | 2.47 | 3.19 | 3.30 |
Fiscal Year End for Verona Pharma PLC American Depositary Share falls in the month of December.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 272 | 257 | 271 | 291 |
Receivables | NA | 11 | 10 | 10 | 12 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 0 | 0 | 0 |
Other Current Assets | NA | 7 | 10 | 7 | 4 |
Total Current Assets | NA | 290 | 277 | 288 | 307 |
Net Property & Equipment | NA | 0 | 0 | 0 | 0 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 1 | 1 | 1 | 1 |
Deposits & Other Assets | NA | 15 | 15 | 15 | 15 |
Total Assets | NA | 308 | 292 | 304 | 323 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 3 | 1 | 2 | 7 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 1 | 0 | 1 | 1 |
Accrued Expenses | NA | 4 | 7 | 7 | 18 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 0 | 0 | 0 | 1 |
Total Current Liabilities | NA | 9 | 9 | 11 | 27 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 48 | 20 | 20 | 20 |
Non-Current Capital Leases | NA | 2 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 0 | 0 | 0 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 59 | 29 | 31 | 46 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 43 | 42 | 42 | 42 |
Capital Surplus | NA | 601 | 601 | 596 | 591 |
Retained Earnings | NA | -388 | -374 | -359 | -350 |
Other Equity | NA | -5 | -5 | -5 | -5 |
Treasury Stock | NA | 2 | 1 | 1 | 1 |
Total Shareholder's Equity | NA | 249 | 264 | 273 | 277 |
Total Liabilities & Shareholder's Equity | NA | 308 | 292 | 304 | 323 |
Total Common Equity | 0 | 249 | 264 | 273 | 277 |
Shares Outstanding | 80.80 | 80.40 | 79.90 | 79.40 | 78.90 |
Book Value Per Share | 0.00 | 3.10 | 3.30 | 3.44 | 3.51 |